Table 1 Clinical characteristics of patients with CESC

n

304

T stage, n (%)

T1

140 (58.1%)

T2

71 (29.5%)

T3

20 (8.3%)

T4

10 (4.1%)

N stage, n (%)

N0

133 (68.9%)

N1

60 (31.1%)

M stage, n (%)

M0

116 (92.1%)

M1

10 (7.9%)

Clinical stage, n (%)

Stage I

162 (54.5%)

Stage II

69 (23.2%)

Stage III

45 (15.2%)

Stage IV

21 (7.1%)

Radiation therapy, n (%)

No

122 (40.1%)

Yes

182 (59.9%)

Primary therapy outcome, n (%)

PD

22 (10.1%)

SD

6 (2.8%)

PR

8 (3.7%)

CR

181 (83.4%)

Race, n (%)

Asian

20 (7.7%)

Black or African American

30 (11.6%)

White

209 (80.7%)

Age, n (%)

 ≤ 50

186 (61.2%)

 > 50

118 (38.8%)

Weight, n (%)

 ≤ 70

138 (50.2%)

 > 70

137 (49.8%)

Height, n (%)

 ≤ 160

133 (51%)

 > 160

128 (49%)

BMI, n (%)

 ≤ 25

100 (38.6%)

 > 25

159 (61.4%)

Histological type, n (%)

Adenosquamous

52 (17.1%)

Squamous cell carcinoma

252 (82.9%)

Histologic grade, n (%)

G1

18 (6.6%)

G2

135 (49.6%)

G3

118 (43.4%)

G4

1 (0.4%)

Menopause status, n (%)

Pre

124 (53.7%)

Peri

25 (10.8%)

Post

82 (35.5%)

Birth control pill history, n (%)

No

89 (56.7%)

Yes

68 (43.3%)

Keratinizing squamous cell carcinoma present, n (%)

No

119 (39.1%)

Yes

185 (60.9%)

OS event, n (%)

Alive

233 (76.6%)

Dead

71 (23.4%)

DSS event, n (%)

Alive

246 (82%)

Dead

54 (18%)

PFI event, n (%)

Alive

233 (76.6%)

Dead

71 (23.4%)

Age, median (IQR)

46 (38, 56.25)